says that she was issuing warnings and no one was listening. >> mccubbin: i don't know cheryl eckardils of her accusations. what i do know is that we were working with the f.d.a. before cheryl went to that plant. >> pelley: it was an f.d.a. inspection that first revealed problems at cidra, and that's why glaxo sent eckard's team in, to resolve those f.d.a. concerns. but eckard says she found much more than the f.d.a. did. f.d.a. inspections of drug plants are only occasional, so it's up to drug companies to police themselves. >> dr. jerry avorn: probably, most drugs are safe that people are taking, but there are scary examples like this that certainly raise questions. >> pelley: dr. jerry avorn of harvard medical school is one of the nation's leading authorities on pharmaceuticals. he says that eckard's story is an extraordinary look at what can happen when there aren't enough investigators to follow up on the federal inspections. >> avorn: the fact that there were so many different kinds of problems, and that there were even other issues about diabetes drugs and antidepressants on t